Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Intracavernous moxisylyte recommended for first-line treatment of ED

Oct. 3, 1997

BioTime completes phase III trial with blood volume plasma extender

Oct. 3, 1997

First registration filing for Unigene's injectable calcitonin product

Oct. 2, 1997

Quinacrine sterilization reviewed

Oct. 2, 1997

New agents for NIDDM presented by Pharmacia & Upjohn

Oct. 1, 1997

Pfizer seeks U.S. and European approval for Viagra

Sep. 30, 1997

Amgen to emphasize calcimimetics program; preliminary phase II results reported for R-568

Sep. 30, 1997

LY-333334: new bone anabolic agent from Lilly

Sep. 30, 1997

SB-244875: a new bone resorption inhibitor

Sep. 29, 1997

Sumitomo prepares bone-selective bisphosphonate-estrogen conjugates

Sep. 29, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 26, 2026
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
Researchers identify innate immune barrier against melanoma
BioWorld
Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live...
Cavalon Therapeutics and Northwestern patent new Cav1.3 blockers
BioWorld Science
Cavalon Therapeutics Inc. and Northwestern University have disclosed new voltage-gated calcium channel Cav1.3 blockers potentially useful for the treatment of...